Please provide your email address to receive an email when new articles are posted on . Candesant Biomedical announced positive results from its pilot study on the targeted alkali thermolysis patch, ...

Hyperhidrosis most commonly affects the armpits, followed by the palms of the hands and the soles of the feet. Impairment of quality of life differs based on where primary hyperhidrosis manifests on ...

Please provide your email address to receive an email when new articles are posted on . Treatment with sofpironium bromide gel reduced the severity of primary axillary hyperhidrosis in a cohort of ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved ...

Sofpironium bromide is a structural analogue of glycopyrrolate, an anticholinergic agent. Positive topline results were announced from 2 identical phase 3 studies evaluating sofpironium bromide in ...

NASHVILLE, Tenn., March 18, 2023 /PRNewswire/ -- Candesant Biomedical ("Candesant"), a private medical device company focused on the development and commercialization of non-invasive treatments for ...

Sofpironium bromide indirectly reduces the rate of sweating by preventing the stimulation of acetylcholine receptors that are located on sweat glands. The Food and Drug Administration (FDA) has ...

The US Food and Drug Administration (FDA) today cleared the first patch to reduce excessive underarm sweating for adults with primary axillary hyperhidrosis. The single-use, disposable, ...

Early commercial payer coverage for the therapy includes Express Scripts, Inc. and OptumRx Company announces DermiraConnect, a new patient access program that will provide patients broad access to ...

- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical Trial ...